Gene Therapy for Mucopolysaccharidosis Type II—A Review of the Current Possibilities
Open Access
- 23 May 2021
- journal article
- review article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 22 (11) , 5490
Abstract
Mucopolysaccharidosis type II (MPS II) is a lysosomal storage disorder based on a mutation in the IDS gene that encodes iduronate 2-sulphatase. As a result, there is an accumulation of glycosaminoglycans—heparan sulphate and dermatan sulphate—in almost all body tissues, which leads to their dysfunction. Currently, the primary treatment is enzyme replacement therapy, which improves the course of the disease by reducing somatic symptoms, including hepatomegaly and splenomegaly. The enzyme, however, does not cross the blood–brain barrier, and no improvement in the function of the central nervous system has been observed in patients with the severe form of the disease. An alternative method of treatment that solves typical problems of enzyme replacement therapy is gene therapy, i.e., delivery of the correct gene to target cells through an appropriate vector. Much progress has been made in applying gene therapy for MPS II, from cellular models to human clinical trials. In this article, we briefly present the history and basics of gene therapy and discuss the current state of knowledge about the methods of this therapy in mucopolysaccharidosis type II.Keywords
This publication has 80 references indexed in Scilit:
- Mucopolysaccharidosis type II in a female carrying a heterozygous stop mutation of the iduronate-2-sulfatase gene and showing a skewed X chromosome inactivationEuropean Journal of Medical Genetics, 2013
- Mucopolysaccharidosis type II in females and response to enzyme replacement therapyAmerican Journal of Medical Genetics Part A, 2012
- Adeno-Associated Virus Antibody Profiles in Newborns, Children, and AdolescentsClinical and Vaccine Immunology, 2011
- Genome editing with engineered zinc finger nucleasesNature Reviews Genetics, 2010
- Characterization of a Novel Mucopolysaccharidosis Type II Mouse Model and Recombinant AAV2/8 Vector-Mediated Gene TherapyMolecules and Cells, 2010
- Prevalence of Serum IgG and Neutralizing Factors Against Adeno-Associated Virus (AAV) Types 1, 2, 5, 6, 8, and 9 in the Healthy Population: Implications for Gene Therapy Using AAV VectorsHuman Gene Therapy, 2010
- Hunter syndrome in an 11‐year old girl on enzyme replacement therapy with idursulfase: brain magnetic resonance imaging features and evolutionJournal of Inherited Metabolic Disease, 2010
- Mucopolysaccharidosis type II in females: Case report and review of literaturePediatric Neurology, 2005
- Construction of a high efficiency retroviral vector for gene therapy of Hunter's syndromeThe Journal of Gene Medicine, 2002
- Observed incidence of tumorigenesis in long-term rodent studies of rAAV vectorsGene Therapy, 2001